These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 24901320)

  • 21. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition.
    Weeden CE; Ah-Cann C; Holik AZ; Pasquet J; Garnier JM; Merino D; Lessene G; Asselin-Labat ML
    Oncogene; 2018 Aug; 37(32):4475-4488. PubMed ID: 29743589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors.
    Korfi K; Smith M; Swan J; Somervaille TC; Dhomen N; Marais R
    Cell Death Dis; 2016 Apr; 7(4):e2177. PubMed ID: 27054332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53.
    Yang MC; Lin RW; Huang SB; Huang SY; Chen WJ; Wang S; Hong YR; Wang C
    Cell Cycle; 2016; 15(3):394-402. PubMed ID: 26694174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists.
    Schroeder GM; Wei D; Banfi P; Cai ZW; Lippy J; Menichincheri M; Modugno M; Naglich J; Penhallow B; Perez HL; Sack J; Schmidt RJ; Tebben A; Yan C; Zhang L; Galvani A; Lombardo LJ; Borzilleri RM
    Bioorg Med Chem Lett; 2012 Jun; 22(12):3951-6. PubMed ID: 22608393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
    Zhang J; Huang K; O'Neill KL; Pang X; Luo X
    Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins.
    Wei J; Kitada S; Rega MF; Emdadi A; Yuan H; Cellitti J; Stebbins JL; Zhai D; Sun J; Yang L; Dahl R; Zhang Z; Wu B; Wang S; Reed TA; Wang HG; Lawrence N; Sebti S; Reed JC; Pellecchia M
    Mol Cancer Ther; 2009 Apr; 8(4):904-13. PubMed ID: 19372563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
    Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
    Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
    Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
    Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins.
    Tanaka Y; Aikawa K; Nishida G; Homma M; Sogabe S; Igaki S; Hayano Y; Sameshima T; Miyahisa I; Kawamoto T; Tawada M; Imai Y; Inazuka M; Cho N; Imaeda Y; Ishikawa T
    J Med Chem; 2013 Dec; 56(23):9635-45. PubMed ID: 24215352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells.
    Takahashi H; Chen MC; Pham H; Matsuo Y; Ishiguro H; Reber HA; Takeyama H; Hines OJ; Eibl G
    Biochim Biophys Acta; 2013 Dec; 1833(12):2980-2987. PubMed ID: 23954445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.
    Peperzak V; Slinger E; Ter Burg J; Eldering E
    Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma.
    Halatsch ME; Kast RE; Dwucet A; Hlavac M; Heiland T; Westhoff MA; Debatin KM; Wirtz CR; Siegelin MD; Karpel-Massler G
    Br J Pharmacol; 2019 Sep; 176(18):3681-3694. PubMed ID: 31222722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
    Chen S; Dai Y; Pei XY; Grant S
    Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.
    Park D; Magis AT; Li R; Owonikoko TK; Sica GL; Sun SY; Ramalingam SS; Khuri FR; Curran WJ; Deng X
    Cancer Res; 2013 Sep; 73(17):5485-96. PubMed ID: 23824742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trichonomas vaginalis metalloproteinase induces apoptosis of SiHa cells through disrupting the Mcl-1/Bim and Bcl-xL/Bim complexes.
    Quan JH; Kang BH; Cha GH; Zhou W; Koh YB; Yang JB; Yoo HJ; Lee MA; Ryu JS; Noh HT; Kwon J; Lee YH
    PLoS One; 2014; 9(10):e110659. PubMed ID: 25343522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
    Xiao Y; Nimmer P; Sheppard GS; Bruncko M; Hessler P; Lu X; Roberts-Rapp L; Pappano WN; Elmore SW; Souers AJ; Leverson JD; Phillips DC
    Mol Cancer Ther; 2015 Aug; 14(8):1837-47. PubMed ID: 26013319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
    Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
    Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.